SCHEMBL982034

SCHEMBL982034

O=C(Cc1cccs1)N1CCC(c2cccs2)=N1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
KMT2A Q03164 4/20 0.50
LMNA P02545 3/20 0.50
GAA P10253 1/20 0.50
HTT P42858 1/20 0.45
KDM4E B2RXH2 6/20 0.45
HSD17B10 Q99714 2/20 0.44
YAP1 P46937 1/20 0.44
TEAD4 Q15561 1/20 0.44
HPGD P15428 1/20 0.44
CASP1 P29466 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MEN1 O00255 3/20 0.44
MAPT P10636 3/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17004399 0.86 ALDH1A1 (0.49) ALDH1A1KMT2ALMNAGAAHTT
SCHEMBL981784 0.83 ALDH1A1 (0.49) ALDH1A1KMT2ALMNAHTTKDM4E
SCHEMBL982617 0.83 ALDH1A1 (0.53) ALDH1A1KMT2ALMNAGAAHTT
SCHEMBL982164 0.83 KDM4E (0.48) ALDH1A1KMT2ALMNAHTTKDM4E
SCHEMBL982401 0.83 ALDH1A1 (0.46) ALDH1A1KMT2ALMNAGAAHTT
SCHEMBL982365 0.80 KDM4E (0.55) ALDH1A1KMT2ALMNAHTTKDM4E
SCHEMBL981499 0.80 ALDH1A1 (0.45) ALDH1A1KMT2ALMNAGAAHTT
SCHEMBL982035 0.80 ALDH1A1 (0.53) ALDH1A1KMT2ALMNAGAAKDM4E
SCHEMBL980554 0.79 HPGD (0.48) ALDH1A1KMT2ALMNAKDM4EHSD17B10
SCHEMBL982411 0.79 MAPT (0.55) ALDH1A1KMT2ALMNAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed
CN-101243048-A 1-acyldihydropyrazol derivatives MERCK PATENT GMBH (DE) 2008-08-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 ALDH1A1 399/4885KMT2A 174/4885LMNA 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.